| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | ACTN3 |
| Uniprot No | Q08043 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 325-608aa |
| 氨基酸序列 | RKLEDFRDYRRLHKPPRIQEKCQLEINFNTLQTKLRLSHRPAFMPSEGKLVSDIANAWRGLEQVEKGYEDWLLSEIRRLQRLQHLAEKFRQKASLHEAWTRGKEEMLSQRDYDSALLQEVRALLRRHEAFESDLAAHQDRVEHIAALAQELNELDYHEAASVNSRCQAICDQWDNLGTLTQKRRDALERMEKLLETIDRLQLEFARRAAPFNNWLDGAVEDLQDVWLVHSVEETQSLLTAHDQFKATLPEADRERGAIMGIQGEIQKICQTYGLRPCSTNPYIT |
| 预测分子量 | 33 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于ACTN3重组蛋白的3篇参考文献示例(注：以下内容为模拟示例，实际文献需根据具体研究查询)：
---
1. **文献名称**：*Expression and Functional Analysis of Recombinant ACTN3 Protein in Skeletal Muscle Cells*
**作者**：North, K.N., et al.
**摘要**：本研究通过大肠杆菌系统成功表达并纯化了重组人源ACTN3蛋白，分析了其在体外骨骼肌细胞中的定位及对肌动蛋白细胞骨架的调控作用。实验表明，ACTN3重组蛋白可增强肌细胞收缩能力，为研究ACTN3基因缺失型(XX型)个体的运动表型提供了分子机制依据。
2. **文献名称**：*Structural Characterization of Recombinant α-Actinin-3 and Its Role in Muscle Metabolism*
**作者**：Mills, M., et al.
**摘要**：通过X射线晶体学解析了重组ACTN3蛋白的三维结构，发现其与ACTN2存在关键结构域差异。进一步功能实验显示，ACTN3重组蛋白能显著促进糖酵解酶的活性，解释了其在快肌纤维能量代谢中的特异性作用。
3. **文献名称**：*ACTN3 R577X Polymorphism and Recombinant Protein Rescue in Muscular Dystrophy Models*
**作者**：Clarkson, P.M., et al.
**摘要**：研究利用重组ACTN3蛋白在ACTN3敲除小鼠模型中进行了功能补偿实验。结果显示，外源性ACTN3蛋白注射可改善肌肉萎缩和运动能力，提示其在治疗ACTN3缺失相关肌肉疾病中的潜在应用价值。
---
如需实际文献，建议通过PubMed或Web of Science检索关键词“recombinant ACTN3 protein”或“α-actinin-3 expression”获取最新研究。
The ACTN3 gene encodes α-actinin-3. a structural protein predominantly expressed in skeletal muscle fast-twitch (type II) fibers. It belongs to the α-actinin family, which stabilizes the actin cytoskeleton and regulates muscle contraction. A common genetic variant (R577X) in ACTN3 results in a premature stop codon, leading to complete deficiency of the protein in approximately 20% of the global population. This polymorphism has been extensively studied in sports science, as α-actinin-3 deficiency is associated with reduced muscle strength and sprint performance but may enhance endurance capacity.
Recombinant ACTN3 protein is engineered to study its molecular functions, interactions, and therapeutic potential. Produced via bacterial or mammalian expression systems, it retains domains critical for binding actin filaments (N-terminal) and mediating protein-protein interactions (C-terminal). Researchers use recombinant ACTN3 to investigate its role in maintaining sarcomere integrity, metabolic regulation, and response to mechanical stress. It also aids in exploring genotype-phenotype relationships in muscle disorders, such as muscular dystrophy or age-related sarcopenia.
Recent studies suggest ACTN3 deficiency may influence muscle adaptation to exercise, glucose metabolism, and disease susceptibility. Recombinant protein tools enable mechanistic studies, drug screening, and development of biologics targeting muscle pathologies. Its applications extend to gene therapy research, particularly for restoring α-actinin-3 in deficient individuals to improve muscle function. Overall, ACTN3 recombinant protein serves as a vital resource for understanding muscle biology and translating genetic insights into clinical or performance-related interventions.
×
